Cytokinetics, Inc. Files for Initial Public Offering
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jan. 27, 2004--Cytokinetics, Inc., the leading biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that specifically target the cytoskeleton, announced today that it has filed with the Securities and Exchange Commission a registration statement relating to the proposed initial public offering of shares of its common stock. All of the shares of common stock sold in the offering will be sold by Cytokinetics, Inc.
Goldman, Sachs & Co. is acting as book-runner and lead manager, and Credit Suisse First Boston, Pacific Growth Equities, LLC and Lazard are acting as co-managers in the offering. When available, a preliminary prospectus relating to these securities may be obtained from Goldman, Sachs & Co.'s prospectus department at 85 Broad Street, New York, New York 10004, by telephone at 212-902-1171 or by faxing a request to 212-902-9316.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.
Cytokinetics, Incorporated is the leading biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that specifically target the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Our focus on the cytoskeleton enables us to develop novel and potentially safer and more effective classes of drugs directed at treatments for cancer, cardiovascular disease, fungal diseases and other diseases. |
